Literature DB >> 9306407

Apoptosis induced in mammalian cells by small peptides that functionally antagonize the Rb-regulated E2F transcription factor.

L R Bandara1, R Girling, N B La Thangue.   

Abstract

A variety of studies implicate the E2F transcription factor as a critical regulator of the mammalian cell cycle. The E2F pathway is aberrant in most, if not all, human tumor cells; therefore, therapeutic regimes that modulate E2F activity may provide an approach for reinstating growth control in situations where normal physiological control is lost. To elucidate the role of E2F in the cell cycle and assess its value as a therapeutic target, we have introduced peptides that functionally antagonize E2F DNA binding activity into mammalian cells. Introduction of these peptides into mammalian tumor cells caused the rapid onset of apoptosis, an outcome that correlates with the inactivation of physiological E2F.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9306407     DOI: 10.1038/nbt0997-896

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


  8 in total

1.  ORC localization in Drosophila follicle cells and the effects of mutations in dE2F and dDP.

Authors:  I Royzman; R J Austin; G Bosco; S P Bell; T L Orr-Weaver
Journal:  Genes Dev       Date:  1999-04-01       Impact factor: 11.361

2.  A small-molecule E2F inhibitor blocks growth in a melanoma culture model.

Authors:  Yihong Ma; Courtney A Kurtyka; Sandhya Boyapalle; Shen-Shu Sung; Harshani Lawrence; Wayne Guida; W Douglas Cress
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

3.  Reduction of total E2F/DP activity induces senescence-like cell cycle arrest in cancer cells lacking functional pRB and p53.

Authors:  Kayoko Maehara; Kimi Yamakoshi; Naoko Ohtani; Yoshiaki Kubo; Akiko Takahashi; Seiji Arase; Nic Jones; Eiji Hara
Journal:  J Cell Biol       Date:  2005-02-14       Impact factor: 10.539

4.  Established and new mouse models reveal E2f1 and Cdk2 dependency of retinoblastoma, and expose effective strategies to block tumor initiation.

Authors:  M Sangwan; S R McCurdy; I Livne-Bar; M Ahmad; J L Wrana; D Chen; R Bremner
Journal:  Oncogene       Date:  2012-01-30       Impact factor: 9.867

Review 5.  The broken cycle: E2F dysfunction in cancer.

Authors:  Lindsey N Kent; Gustavo Leone
Journal:  Nat Rev Cancer       Date:  2019-06       Impact factor: 60.716

6.  Apoptotic and growth-promoting activity of E2F modulated by MDM2.

Authors:  O Loughran; N B La Thangue
Journal:  Mol Cell Biol       Date:  2000-03       Impact factor: 4.272

7.  Determining therapeutic susceptibility in multiple myeloma by single-cell mass accumulation.

Authors:  Arif E Cetin; Mark M Stevens; Nicholas L Calistri; Mariateresa Fulciniti; Selim Olcum; Robert J Kimmerling; Nikhil C Munshi; Scott R Manalis
Journal:  Nat Commun       Date:  2017-11-20       Impact factor: 14.919

8.  Non-overlapping Control of Transcriptome by Promoter- and Super-Enhancer-Associated Dependencies in Multiple Myeloma.

Authors:  Mariateresa Fulciniti; Charles Y Lin; Mehmet K Samur; Michael A Lopez; Irtisha Singh; Matthew A Lawlor; Raphael E Szalat; Christopher J Ott; Herve' Avet-Loiseau; Kenneth C Anderson; Richard A Young; James E Bradner; Nikhil C Munshi
Journal:  Cell Rep       Date:  2018-12-26       Impact factor: 9.423

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.